{"id":"experimental-tralokinumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Conjunctivitis"}]},"_chembl":{"chemblId":"CHEMBL1743081","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T16:12:44.481356","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-13 is a critical mediator of type 2 inflammation involved in conditions like atopic dermatitis and asthma. By neutralizing IL-13, tralokinumab reduces the downstream inflammatory cascade, including IgE production, eosinophil recruitment, and barrier dysfunction. This mechanism addresses the underlying pathophysiology of IL-13-driven allergic and inflammatory diseases.","oneSentence":"Tralokinumab is a monoclonal antibody that blocks interleukin-13 (IL-13), a key cytokine driving type 2 inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:01.178Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate-to-severe atopic dermatitis"},{"name":"Asthma (type 2 inflammation)"}]},"_fixedFields":["pubmed(17)","modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT03761537","phase":"PHASE3","title":"Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-12-13","conditions":"Atopic Dermatitis","enrollment":277},{"nctId":"NCT03556592","phase":"PHASE1","title":"Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-08-13","conditions":"Atopic Dermatitis","enrollment":40},{"nctId":"NCT02194699","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-10-30","conditions":"Uncontrolled Asthma","enrollment":856},{"nctId":"NCT02036580","phase":"PHASE2","title":"D2212C00002 J-Phase II Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-01","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Experimental: Tralokinumab","genericName":"Experimental: Tralokinumab","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tralokinumab is an interleukin-13 inhibitor, classified as an antibody, used to treat various skin conditions. It is being studied in clinical trials for conditions such as Chronic Spontaneous Urticaria, Hidradenitis Suppurativa, Psoriasis, Atopic Dermatitis, and CTCL/ Mycosis Fungoides.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}